|
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NOT_RECRUITINGPhase 3Sponsored by Definium Therapeutics US, Inc.
No longer actively recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2024-12-11
Est. completion2026-05
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations36 sites
View on ClinicalTrials.gov →
NCT06741228
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Eligibility
Age: 18 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness
Conditions2
AnxietyGeneralized Anxiety Disorder
Interventions1
Locations36 sites
Lighthouse Psychiatry
Scottsdale Research Institute
Kadima Neuropsychiatry Institute
UCSF Department of Neurology
Psychedelic Science Institute
Find trials near these locations
All trials in ArizonaAll trials in CaliforniaAll trials in ColoradoAll trials in FloridaAll trials in GeorgiaAll trials in IllinoisAll trials in MassachusettsAll trials in MissouriAll trials in New YorkAll trials in OhioAll trials in OregonAll trials in PennsylvaniaAll trials in TennesseeAll trials in TexasAll trials in Washington
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2024-12-11
Est. completion2026-05
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations36 sites
View on ClinicalTrials.gov →
NCT06741228